Safety Evaluation of Large-Scale Administration of a Novel Human Diploid (SV-1) Cell Line-Derived Varicella Attenuated Live Vaccine in Children 7–12 Years Old
Yuanyuan Zhu, Yurong Li, Jing Yu, Borong Xu, Xun Li, Ran Hu, Xiaozhe Song, Yonghong Sun, Dongsheng Liu, Yuan Ren, Xiang Sun, Zhiguo Wang · 2025
Read Safety Evaluation of Large-Scale Administration of a Novel Human Diploid (SV-1) Cell Line-Derived Varicella Attenuated Live Vaccine in Children 7–12 Years Old by Yuanyuan Zhu, Yurong Li, Jing Yu, Borong Xu, Xun Li, Ran Hu, Xiaozhe Song, Yonghong Sun, Dongsheng Liu, Yuan Ren, Xiang Sun, Zhiguo Wang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12846628.txt.
Description
Yuanyuan Zhu and eleven co-authors check the safety of a new chickenpox vaccine given to school children, in a 2025 study. The vaccine is grown in a human cell line called SV-1, the first vaccine made on that base. The study used health records from Jiangsu Province in China. It covered children aged seven to twelve who received the vaccine between July 2024 and March 2025.
Reports of side effects after vaccination were drawn from the national reporting system. The team counted how often such events were reported and described their types and patterns across age and sex groups. Large real-world checks like this matter because rare problems may not appear in smaller pre-release trials. The findings inform parents, schools, and health officials running the program.
Catalog record
| CREATOR | Yuanyuan Zhu, Yurong Li, Jing Yu, Borong Xu, Xun Li, Ran Hu, Xiaozhe Song, Yonghong Sun, Dongsheng Liu, Yuan Ren, Xiang Sun, Zhiguo Wang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |